We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Oral Bacteria Linked to Risk of Intracerebral Hemorrhage

By LabMedica International staff writers
Posted on 09 Mar 2016
Print article
Image: Streptococcus mutans colonies growing on Mitis Salivarius Bacitracin agar showing convex, pale blue colonies with granular frosted glass appearance (Photo courtesy of Drs. Rajan and Shivani Dhawan).
Image: Streptococcus mutans colonies growing on Mitis Salivarius Bacitracin agar showing convex, pale blue colonies with granular frosted glass appearance (Photo courtesy of Drs. Rajan and Shivani Dhawan).
Physicians have an increased understanding of patients entering the hospital for acute stroke, and the association between certain types of stroke and the presence of the oral bacteria centronuclear myopathies gene (cnm)-positive Streptococcus mutans.

Small vessel diseases (SVDs) of the brain such as cerebral microbleeds (CMBs), lacunar infarcts, and white matter lesions are important biomarkers of vascular injury and burden of brain dysfunction. The underlying mechanisms and risk factors of the SVDs of the brain are poorly understood.

A team of scientists led by those at the National Cerebral and Cardiovascular Center (NCVC; Osaka, Japan) enrolled patients admitted to the NCVC because of acute heart disease, between February and August 2014, consisting of 67 subjects with ischemic stroke, 5 with transient ischemic attack, and 27 with intracerebral hemorrhage (ICH). The cnm gene in S. mutans isolated from saliva was screened using polymerase chain reaction (PCR) techniques and its collagen-binding activities examined. Oral saliva and dental plaque specimens were collected from the subjects in the first three days following admission.

Oral samples were inoculated on Mitis-Salivarius medium with bacitracin (MSB, 100 U/mL; Sigma-Aldrich; St. Louis, MO, USA) and 15% sucrose (MSB agar) and anaerobically incubated at 37 °C for 48 hours. S. mutans strains were isolated morphologically and all strains were anaerobically grown in brain heart infusion (BHI) broth (Difco Laboratories; Detroit, MI, USA) at 37 °C for 24 hours. DNA of each strain was extracted. S. mutans and cnm gene encoding CBP was screened using polymerase chain reaction techniques. MKD primer32 was used to detect S. mutans and cnm primer was used to identify cnm gene33. A collagen-binding assay with type I collagen was conducted to examine collagen-binding activities of each isolated S. mutans strain.

Eleven cases showed Streptococcus mutans strains positive for cnm. The presence of cnm-positive Streptococcus mutans was significantly associated with ICH and increased number of deep CMBs. In subjects positive for Streptococcus mutans, collagen binding activity was positively correlated with the number of deep CMBs. The authors hypothesize that the S. mutans bacteria may bind to blood vessels weakened by age and high blood pressure, causing arterial ruptures in the brain, leading to small or large hemorrhages.


Robert P. Friedland, MD, a professor of Neurology and co-author of the study, said. “This study shows that oral health is important for brain health. People need to take care of their teeth because it is good for their brain and their heart as well as their teeth. The study and related work in our laboratories have shown that oral bacteria are involved in several kinds of stroke, including brain hemorrhages and strokes that lead to dementia.” The study was published online on February 5, 2016, in the journal Scientific Reports.

Related Links:

National Cerebral and Cardiovascular Center
Sigma-Aldrich
Difco Laboratories 


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
AST Cards
Antimicrobial Susceptibility Testing Cards
New
Calprotectin Assay
Fecal Calprotectin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.